285 related articles for article (PubMed ID: 36033444)
1. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Attili I; Valenza C; Santoro C; Antonarelli G; Trillo Aliaga P; Del Signore E; Catania C; Spitaleri G; Passaro A; de Marinis F
Front Oncol; 2022; 12():980765. PubMed ID: 36033444
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White MN; Piper-Vallillo AJ; Gardner RM; Cunanan K; Neal JW; Das M; Padda SK; Ramchandran K; Chen TT; Sequist LV; Piotrowska Z; Wakelee HA
Clin Lung Cancer; 2022 May; 23(3):e210-e221. PubMed ID: 34887193
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Zhang X; Zhou Y; Chen H; Chen C; Lin Z; He LN; Du W; Chen T; Hong S; Fu S
Front Immunol; 2022; 13():1015444. PubMed ID: 36248788
[TBL] [Abstract][Full Text] [Related]
6. Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E; Hulo P; Guardiolle V; Bodot L; Rabeau A; Porte M; Hiret S; Demontrond P; Curcio H; Boudoussier A; Veillon R; Mayenga M; Dumenil C; Chatellier T; Gourraud PA; Mazieres J; Bennouna J
Cancer Immunol Immunother; 2023 Jun; 72(6):1881-1890. PubMed ID: 36690799
[TBL] [Abstract][Full Text] [Related]
7. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Elkrief A; Riccuiti B; Alessi JV; Fei T; Kalvin HL; Egger JV; Rizvi H; Thummalapalli R; Lamberti G; Plodkowski A; Hellmann MD; Kris MG; Arcila ME; Baine MK; Rudin CM; Lito P; Ladanyi M; Schoenfeld AJ; Riely GJ; Awad MM; Arbour KC
Oncologist; 2023 Nov; 28(11):978-985. PubMed ID: 37589215
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
11. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
12. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
[TBL] [Abstract][Full Text] [Related]
13. First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Tanimura K; Takeda T; Kataoka N; Yoshimura A; Nakanishi K; Yamanaka Y; Yoshioka H; Honda R; Uryu K; Fukui M; Chihara Y; Takei S; Kawachi H; Yamada T; Tamiya N; Okura N; Yamada T; Murai J; Shiotsu S; Kurata T; Takayama K
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894357
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Danesi V; Massa I; Foca F; Delmonte A; Crinò L; Bronte G; Ragonesi M; Maltoni R; Manunta S; Cravero P; Andrikou K; Priano I; Balzi W; Gentili N; Burke T; Altini M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139641
[TBL] [Abstract][Full Text] [Related]
15. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract][Full Text] [Related]
17. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
Liu Y; Gao Y; Wang Y; Zhao C; Zhang Z; Li B; Zhang T
BMC Cancer; 2022 Nov; 22(1):1175. PubMed ID: 36376839
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
19. A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A; Foca F; Nanni O; Chiumente M; Coppola M; Baldo P; Orzetti S; Enrico F; Ladisa V; Lerose R; Nardulli P; Maiolino P; Gradellini F; Gasbarro AR; Carrucciu G; Provasi R; Cappelletto PC; Pasqualini A; Vecchia S; Veraldi M; De Francesco AE; Crinò L; Delmonte A; Masini C
Front Oncol; 2024; 14():1351995. PubMed ID: 38601759
[TBL] [Abstract][Full Text] [Related]
20. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and
Asad Zadeh Vosta Kolaei F; Cai B; Kanakamedala H; Kim J; Doban V; Zhang S; Shi M
Front Oncol; 2022; 12():786124. PubMed ID: 35280795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
